Xavier Verhelst
Papers
1
Total Citations
17
H-Index
1
About
Xavier Verhelst is a leading researcher at the intersection of clinical chemistry and glycobiology, with a primary focus on developing innovative diagnostic tools for chronic inflammatory diseases. His most notable contribution is the pioneering use of Endoglycosidase S (EndoS) to create a simplified, direct clinical chemistry procedure for assessing serum IgG undergalactosylation—a hallmark of conditions like rheumatoid arthritis, Crohn’s disease, lupus, and steatohepatitis. This work, detailed in his highly cited 2018 paper (17 citations), replaces complex, multi-step glycan analysis with a streamlined assay, significantly advancing the feasibility of routine clinical screening for inflammation-driven pathologies. Verhelst’s research bridges fundamental glycobiology and practical diagnostics, offering a scalable method to monitor disease activity and therapeutic response. His achievements include establishing a direct link between IgG glycosylation patterns and chronic inflammatory states, with potential applications in personalized medicine. By enabling rapid, cost-effective assessment of undergalactosylation, Verhelst’s work has profound implications for early detection and management of autoimmune and metabolic diseases, positioning him as a key innovator in translational glycobiology.
Research Focus
Key Achievements
Top Papers
- 1